ASM ASM International N.V.

ASMI Share Buyback Update August 10 – 14, 2020

ASMI Share Buyback Update August 10 – 14, 2020

Almere, The Netherlands

August 17, 2020, 5:45 p.m. CET

ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASMI's current share buyback program.

DateRepurchased sharesAverage priceRepurchased value
August 10, 202016,000€ 126.63€ 2,026,043
August 11, 20204,500€ 126.98€ 571,388
August 12, 2020---
August 13, 2020---
August 14, 2020391€ 127.25€ 49,755
Total20,891€ 126.71€ 2,647,186

These repurchases were made as part of the €100 million share buyback program announced on June 2, 2020. Of the total program, 13.5% has been repurchased. For further details including individual transaction information please visit: .

About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at .

Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

CONTACT

Investor and media contact:

Victor Bareño

T:

E:

Attachment

EN
17/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ASM International N.V.

Marc Zwartsenburg ... (+2)
  • Marc Zwartsenburg
  • CEFA

ING Benelux Favourites/Weekly performance and valuation update

In this publication we update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 26 April 2023, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune.

Anthony Dick ... (+5)
  • Anthony Dick
  • Marc Lavaud
  • Martin Marandon-Carlhian
  • Maxime Kogge
  • Michael Foundoukidis

ODDO : Véhicules électriques : d’un excès à l’autre ?

Le momentum autour de l’électrification, moins favorable dernièrement, a conduit à un changement profond de perception, passant d’un optimisme sans doute excessif à un pessimisme qui le semble tout autant. En effet, si nous avons revu en baisse nos hypothèses, nous visons néanmoins toujours une croissance dans les années à venir (y compris cette année), bien supérieure à celle du marché automobile dans son ensemble. Face à ces changements, tous les acteurs au sein de la chaîne de...

Anthony Dick ... (+5)
  • Anthony Dick
  • Marc Lavaud
  • Martin Marandon-Carlhian
  • Maxime Kogge
  • Michael Foundoukidis

ODDO : Electric vehicles: from one extreme to another?

With momentum around electrification less favourable of late, we have seen a major shift in perception, from doubtless overly rose-tinted optimism to what looks to be similarly excessive pessimism. While we have reduced our BEV assumptions, we nonetheless still anticipate growth in the next few years (including this year), well ahead of that of the automotive market as a whole. In the face of these changes, the players in the value chain (mines, semiconductors, auto) are differen...

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Florent Laroche-Joubert
  • Jean-Baptiste Rouphael
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/03/2024

L’année 2024 sera marquée par l’élection présidentielle américaine et l’annonce des rabais pour les 10 médicaments dont les prix sont dorénavant négociés directement par Medicare dans le cadre de l’IRA. Nous tablons sur une croissance des BPA 24e de 8% et relevons nos OC de 1% en moyenne. Nous privilégions GSK (Surperformance) qui allie valorisation attractive, croissance et newsflow. Nous maintenons notre recommandation Surperformance sur Sanofi qui devrait bénéficier d’un catalyseur...

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Florent Laroche-Joubert
  • Jean-Baptiste Rouphael
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/13/2024

2024 is set to be marked by the US presidential election and the announcement of rebates for the 10 drugs for which prices are now negotiated directly through Medicare under the IRA. We forecast EPS 24e growth of 8% and lift our target prices by 1% on average. We prefer GSK (Outperform) which combines an attractive valuation, growth and clinical newsflow. We maintain our Outperform rating on Sanofi which should benefit from a transformative clinical catalyst in H1. We lower our rating...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch